Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography

被引:7
作者
Beyer, Leonie [1 ]
Brendel, Matthias [1 ]
Scheiwein, Franziska [1 ]
Sauerbeck, Julia [1 ]
Hosakawa, Chisa [2 ]
Alberts, Ian [3 ]
Shi, Kuangyu [3 ]
Bartenstein, Peter [1 ]
Ishii, Kazunari [2 ]
Seibyl, John [4 ]
Cumming, Paul [3 ,5 ,6 ]
Rominger, Axel [3 ]
机构
[1] LMU, Dept Nucl Med, Univ Hosp Munich, Munich, Germany
[2] Kindai Univ, Dept Radiol, Osaka, Japan
[3] Univ Hosp Bern, Dept Nucl Med, Inselspital, Bern, Switzerland
[4] Invicro, New Haven, CT USA
[5] Queensland Univ Technol, Sch Psychol & Counseling, Brisbane, Qld, Australia
[6] Queensland Univ Technol, IHBI, Brisbane, Qld, Australia
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Alzheimer's disease; amyloid-beta; biomarkers; dementia; mild cognitive impairment; positron emission tomography; WHITE-MATTER REFERENCE; STRUCTURAL MRI; PET; ASSOCIATION; CONVERSION; DIAGNOSIS; CRITERIA;
D O I
10.3233/JAD-190818
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Amyloid-beta (A beta) accumulation in brain of patients with suspected Alzheimer's disease (AD) can be assessed by positron emission tomography (PET) in vivo. While visual classification prevails in the clinical routine, semiquantitative PET analyses may enable more reliable evaluation of cases with a visually uncertain, borderline A beta accumulation. Objective: We evaluated different analysis approaches (visual/semiquantitative) to find the most accurate and sensitive interpretation of A beta-PET for predicting risk of progression from mild cognitive impairment (MCI) to AD. Methods: Based on standard uptake value (SUV) ratios of a cortical-composite volume of interest of F-18-AV45-PET from MCI subjects (n= 396, ADNI database), we compared three different reference region (cerebellar grey matter, CBL; brainstem, BST; white matter, WM) normalizations and the visual read by receiver operator characteristics for calculating a hazard ratio (HR) for progression to Alzheimer's disease dementia (ADD). Results: During a mean follow-up time of 45.6 +/- 13.0 months, 28% of the MCI cases (110/396) converted to ADD. Among the tested methods, the WM reference showed best discriminatory power and progression-risk stratification (HRWM of 4.4 [2.6-7.6]), but the combined results of the visual and semiquantitative analysis with all three reference regions showed an even higher discriminatory power. Conclusion: A multi-analytical composite of visual and semiquantitative reference tissue analyses of F-18-AV45-PET gave improved risk stratification for progression from MCI to ADD relative to performance of single read-outs. This optimized approach is of special interest for prospective treatment trials, which demand a high accuracy.
引用
收藏
页码:101 / 112
页数:12
相关论文
共 35 条
[1]   Unified segmentation [J].
Ashburner, J ;
Friston, KJ .
NEUROIMAGE, 2005, 26 (03) :839-851
[2]   Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden [J].
Blautzik, Janusch ;
Brendel, Matthias ;
Sauerbeck, Julia ;
Kotz, Sebastian ;
Scheiwein, Franziska ;
Bartenstein, Peter ;
Seibyl, John ;
Rominger, Axel .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) :1364-1374
[3]   Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study [J].
Boccardi, Marina ;
Altomare, Daniele ;
Ferrari, Clarissa ;
Festari, Cristina ;
Guerra, Ugo Paolo ;
Paghera, Barbara ;
Pizzocaro, Claudio ;
Lussignoli, Giulia ;
Geroldi, Cristina ;
Zanetti, Orazio ;
Cotelli, Maria Sofia ;
Turla, Marinella ;
Borroni, Barbara ;
Rozzini, Luca ;
Mirabile, Dario ;
Defanti, Carlo ;
Gennuso, Michele ;
Prelle, Alessandro ;
Gentile, Simona ;
Morandi, Alessandro ;
Vollaro, Stefano ;
Dalla Volta, Giorgio ;
Bianchetti, Angelo ;
Conti, Marta Zaffira ;
Cappuccio, Melania ;
Carbone, Pasqualina ;
Bellandi, Daniele ;
Abruzzi, Luciano ;
Bettoni, Luigi ;
Villani, Daniele ;
Raimondi, Maria Clara ;
Lanari, Alessia ;
Ciccone, Alfonso ;
Facchi, Emanuela ;
Di Fazio, Ignazio ;
Rozzini, Renzo ;
Boffelli, Stefano ;
Manzoni, Laura ;
Salvi, Giovanni Pietro ;
Cavaliere, Sabina ;
Belotti, Gloria ;
Avanzi, Stefano ;
Pasqualetti, Patrizio ;
Muscio, Cristina ;
Padovani, Alessandro ;
Frisoni, Giovanni B. .
JAMA NEUROLOGY, 2016, 73 (12) :1417-1424
[4]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[5]   Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction [J].
Brendel, Matthias ;
Hoegenauer, Marcus ;
Delker, Andreas ;
Sauerbeck, Julia ;
Bartenstein, Peter ;
Seibyl, John ;
Rominger, Axel .
NEUROIMAGE, 2015, 108 :450-459
[6]   [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment [J].
Bruck, A. ;
Virta, J. R. ;
Koivunen, J. ;
Koikkalainen, J. ;
Scheinin, N. M. ;
Helenius, H. ;
Nagren, K. ;
Helin, S. ;
Parkkola, R. ;
Viitanen, M. ;
Rinne, J. O. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (10) :1567-1572
[7]   Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region [J].
Chen, Kewei ;
Roontiva, Auttawut ;
Thiyyagura, Pradeep ;
Lee, Wendy ;
Liu, Xiaofen ;
Ayutyanont, Napatkamon ;
Protas, Hillary ;
Luo, Ji Luo ;
Bauer, Robert ;
Reschke, Cole ;
Bandy, Daniel ;
Koeppe, Robert A. ;
Fleisher, Adam S. ;
Caselli, Richard J. ;
Landau, Susan ;
Jagust, William J. ;
Weiner, Michael W. ;
Reiman, Eric M. .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (04) :560-566
[8]   Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC) [J].
Chincarini, A. ;
Peira, E. ;
Morbelli, S. ;
Pardini, M. ;
Bauckneht, M. ;
Arbizu, J. ;
Castelo-Branco, M. ;
Buesing, K. A. ;
de Mendonca, A. ;
Didici, M. ;
Dottorini, M. ;
Engelborghs, S. ;
Ferrarese, C. ;
Frisoni, G. B. ;
Garibotto, V ;
Guedj, E. ;
Hausner, L. ;
Hugon, J. ;
Verhaeghe, J. ;
Mecocci, P. ;
Musarra, M. ;
Queneau, M. ;
Riverol, M. ;
Santana, I ;
Guerra, U. P. ;
Nobili, F. .
NEUROIMAGE-CLINICAL, 2019, 23
[9]   Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework [J].
Chiotis, Konstantinos ;
Saint-Aubert, Laure ;
Boccardi, Marina ;
Gietl, Anton ;
Picco, Agnese ;
Varrone, Andrea ;
Garibotto, Valentina ;
Herholz, Karl ;
Nobili, Flavio ;
Nordberg, Agneta .
NEUROBIOLOGY OF AGING, 2017, 52 :214-227
[10]   Use of Florbetapir-PET for Imaging β-Amyloid Pathology [J].
Clark, Christopher M. ;
Schneider, Julie A. ;
Bedell, Barry J. ;
Beach, Thomas G. ;
Bilker, Warren B. ;
Mintun, Mark A. ;
Pontecorvo, Michael J. ;
Hefti, Franz ;
Carpenter, Alan P. ;
Flitter, Matthew L. ;
Krautkramer, Michael J. ;
Kung, Hank F. ;
Coleman, R. Edward ;
Doraiswamy, P. Murali ;
Fleisher, Adam S. ;
Sabbagh, Marwan N. ;
Sadowsky, Carl H. ;
Reiman, P. Eric M. ;
Zehntner, Simone P. ;
Skovronsky, Daniel M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (03) :275-283